118 CHA

British MHRA agency warns that in women of fertile age and overweight the treatment with tirzepatida (Mounjaro) For diabetes and obesity, this medicine It can reduce the effectiveness of the pill, so they are urged to use a contraceptive method that is not oral. The notice comes after confirming 40 cases of users who have become pregnant despite taking the pill.

The recommendation appears in a New guide aimed at patients published by the British regulator in which he indicates that women under treatment with GLP-1 agonists must use effective contraceptives while taking these medications and must Wait up to two months after suspending them before trying to get pregnant in the case of Semaglutida (Wegovy, Ozempic and Rybelsus) or one if it is Mounjaro. With liraglutida this waiting time is not necessary after the interruption of the treatment.

“If you prescribe Mounjaro (Tirzepatida) and is using an oral contraceptive (the pill), use a non-oral form (such as condoms, IUD or implant) of contraception in addition to its pill for four weeks after starting to take GLP-1 medications and for four weeks after any increase in the dose,” says the guide.

It also indicates that if the woman becomes pregnant while she is in the case of LPG-1, she must consult with a health professional and stop taking the medication as soon as possible.

These drugs should not be used during pregnancy, if the woman is trying to get pregnant or during breastfeeding, although the recommendation is based on a precautionary principle, since the regulator warns of the lack of security data in this regard. In studies in animals it has been seen that LPG-1 can be teratogenic but there are no data in humans.

In Spain, Mounjaro’s technical record indicates that the interaction observed with oral contraceptives is not considered clinically relevant and states that a dose adjustment is not necessary. It does notice that its use in pregnancy or women of childbearing age is not recommended who do not use contraceptive methods, and that should not be taken during breastfeeding, for the same reason pointed out by the MHRA of lack of security data.

Although these medications are authorized for the treatment of type 2 diabetes or obesity, their use has shot for aesthetic reasons, which increases their use without proper medical follow -up. The MHRA Security Director, Alison Cave, recalled that: “These medications should not be used as cosmetic treatments or as rapid weight loss solutions.” In addition, he reiterated that patients should consult with health professionals and read the prospects carefully, since the guide published by the British regulator does not replace individualized medical advice.